对二苯并-30-冠-10(DB 30 C 10)和苯并-15-冠-5(B 15 C 5)的紫外分光光度测定法进行了研究。结果表明,DB 30 C 10在2.0×10^(-5)～2.4×10^(-4)mol/L 和 B 15 C 5在3.40×10^(-9)～4.1×10^(-4)mol/L 范围内遵守比耳定...对二苯并-30-冠-10(DB 30 C 10)和苯并-15-冠-5(B 15 C 5)的紫外分光光度测定法进行了研究。结果表明,DB 30 C 10在2.0×10^(-5)～2.4×10^(-4)mol/L 和 B 15 C 5在3.40×10^(-9)～4.1×10^(-4)mol/L 范围内遵守比耳定律。给出了两种试剂在不同溶液中的λ_(max)和ε值。展开更多
目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB...目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB1表达对肺腺癌增殖的影响仍不清楚。本研究探讨了GPRC5A调控的ABCB1表达对肺腺癌增殖的影响。方法我们采用RT-PCR、Western-blot或免疫组化实验,分析ABCB1在肺腺癌细胞系、人肺腺癌组织以及GPRC5A基因敲除小鼠和野生型小鼠的气管上皮细胞和肺组织中的表达。采用细胞计数试剂盒-8(CCK-8)分析GPRC5A基因敲除小鼠气管上皮细胞对化疗药物的敏感性。采用皮下肿瘤形成实验探讨下调ABCB1表达是否可抑制体内肺腺癌增殖。采用免疫荧光和免疫沉淀实验研究GPRC5A和ABCB1之间潜在的调控关系。结果ABCB1在肺腺癌细胞系和人类肺腺癌组织中表达上调。GPRC5A基因敲除小鼠的气管上皮细胞及肺组织的ABCB1表达高于野生型小鼠。与GPRC5A野生型小鼠的气管上皮细胞相比,GPRC5A基因敲除小鼠的气管上皮细胞对塔立奇达和多柔比星更敏感。注射移植细胞28天后,接受ABCB1基因敲除细胞移植的GPRC5A-/-C57BL/6小鼠的肺肿瘤的体积和重量均明显低于野生型细胞移植小鼠(P=0.0043,P=0.0060)。此外,免疫荧光和免疫沉淀实验表明,GPRC5A通过直接结合方式调控ABCB1的表达。结论GPRC5A通过抑制ABCB1表达降低肺腺癌增殖。GPRC5A调节ABCB1表达的途径有待研究。展开更多
背景:诱导骨髓基质干细胞成骨条件的优化与探讨是再生医学研究的热点。前期实验发现Wnt7b在骨发育中的作用,此次实验是前期工作的延续。目的:构建Wnt7b重组反转录病毒载体,观察其在C3H10T1/2中的表达。设计、时间及地点:细胞学体外观察,...背景:诱导骨髓基质干细胞成骨条件的优化与探讨是再生医学研究的热点。前期实验发现Wnt7b在骨发育中的作用,此次实验是前期工作的延续。目的:构建Wnt7b重组反转录病毒载体,观察其在C3H10T1/2中的表达。设计、时间及地点:细胞学体外观察,于2005-01/2008-08在华盛顿大学医学院和同济大学附属第十人民医院中心实验室完成。材料:pXy-Wnt7b购于ATCC公司,载体pCIG-IRES-EGFP,pLef-Luciferase,pCMV-Rennilla,反转录病毒载体pSFG和包装细胞GP293由华盛顿大学医学院提供。方法:用多步亚克隆技术构建目的基因Wnt7b和标记基因加强型绿色荧光蛋白(enhanced green fluorescent protein,EGFP)双表达重组反转录病毒载体pSFG-Wnt7b-IRES-EGFP,在条件培养液中经GP293包装,并在常规培养液中释放出假病毒并将其转染C3H10T1/2细胞,检测成骨活性诱导中的作用和荧光素酶报告基因检测信号转导通路。主要观察指标:①Wnt7b重组反转录病毒转染C3H10T1/2细胞的表达。②Wnt7b诱导C3H10T1/2碱性磷酸酶生成分析。③Wnt7b信号转导分析。结果:构建目的基因的Wnt7b和标记基因EGFP双表达重组反转录病毒载体能够高效地表达,转染C3H10T1/2细胞后能诱导碱性磷酸酶的生成。Wnt7b信号转导分析可见Wnt7b成骨作用通过Noncanonical途径。结论:Wnt7b在C3H10T1/2中能高效表达,能显著诱导骨发育的重要标志--碱性磷酸酶的生成,Noncanonical途径在其中起重要作用。展开更多
AIM To clarify the association between aldo-keto reductase family 1 member B10(AKR1B10) expression and hepatocarcinogenesis after hepatitis C virus eradication.METHODS In this study,we enrolled 303 chronic hepatitis C...AIM To clarify the association between aldo-keto reductase family 1 member B10(AKR1B10) expression and hepatocarcinogenesis after hepatitis C virus eradication.METHODS In this study,we enrolled 303 chronic hepatitis C patients who had achieved sustained virological response(SVR) through interferon-based antiviral therapy. Pretreatment AKR1B10 expression in the liver was immunohistochemically assessed and quantified as a percentage of positive staining area by using image-analysis software. A multivariate Cox analysis was used to estimate the hazard ratios(HRs) of AKR1B10 expression for hepatocellular carcinoma(HCC) development after achieving SVR. The cumulative incidences of HCC development were evaluated using Kaplan-Meier analysis and the log-rank test.RESULTS Of the 303 chronic hepatitis C patients,153(50.5%) showed scarce hepatic AKR1B10 expression,quantified as 0%,which was similar to the expression in control normal liver tissues. However,the remaining 150 patients(49.5%) exhibited various degrees of AKR1B10 expression in the liver,with a maximal AKR1B10 expression of 73%. During the median follow-up time of 3.6 years(range 1.0-10.0 years),8/303 patients developed HCC. Multivariate analysis revealed that only high AKR1B10 expression(≥ 8%) was an independent risk factor for HCC development(HR = 15.4,95%CI: 1. 8- 1 3 2. 5,P = 0. 0 1 2). T h e 5- y e a r c u m u l a t i v e incidences of HCC development were 13.7% and 0.5% in patients with high and low AKR1B10 expression,respectively(P < 0.001). During the follow-up period after viral eradication,patients expressing high levels of AKR1B10 expressed markedly higher levels of alanine aminotransferase and α-fetoprotein than did patients exhibiting low AKR1B10 expression.CONCLUSION Chronic hepatitis C patients expressing high levels of hepatic AKR1B10 had an increased risk of HCC development even after SVR.展开更多
Introduction:ATP-binding cassette subfamily B member 1(ABCB1) and subfamily C member 10(ABCCIO) proteins are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substan...Introduction:ATP-binding cassette subfamily B member 1(ABCB1) and subfamily C member 10(ABCCIO) proteins are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substances and chemotherapeutic drugs out of cells.Cabazitaxel is a novel taxane that differs from paclitaxel by its lower affinity for ATP-binding cassette(ABC) transporters.Methods:We determined the effects of cabazitaxel,a novel tubulin-binding taxane,and paclitaxel on paclitaxelresistant,ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant,ABCC10-overexpressing HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the ABCB1 transporter.Results:Decreased resistance to cabazitaxel compared with paclitaxel was observed in KB-C2,LLC-MDR1-WT,and HEK293/ABCC10 cells.Moreover,cabazitaxel had low efficacy,whereas paclitaxel had high efficacy in stimulating the ATPase activity of ABCB1,indicating a direct interaction of both drugs with the transporter.Conclusion:ABCB1 and ABCC10 are not primary resistance factors for cabazitaxel compared with paclitaxel,suggesting that cabazitaxel may have a low affinity for these efflux transporters.展开更多
文摘对二苯并-30-冠-10(DB 30 C 10)和苯并-15-冠-5(B 15 C 5)的紫外分光光度测定法进行了研究。结果表明,DB 30 C 10在2.0×10^(-5)～2.4×10^(-4)mol/L 和 B 15 C 5在3.40×10^(-9)～4.1×10^(-4)mol/L 范围内遵守比耳定律。给出了两种试剂在不同溶液中的λ_(max)和ε值。
文摘目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB1表达对肺腺癌增殖的影响仍不清楚。本研究探讨了GPRC5A调控的ABCB1表达对肺腺癌增殖的影响。方法我们采用RT-PCR、Western-blot或免疫组化实验,分析ABCB1在肺腺癌细胞系、人肺腺癌组织以及GPRC5A基因敲除小鼠和野生型小鼠的气管上皮细胞和肺组织中的表达。采用细胞计数试剂盒-8(CCK-8)分析GPRC5A基因敲除小鼠气管上皮细胞对化疗药物的敏感性。采用皮下肿瘤形成实验探讨下调ABCB1表达是否可抑制体内肺腺癌增殖。采用免疫荧光和免疫沉淀实验研究GPRC5A和ABCB1之间潜在的调控关系。结果ABCB1在肺腺癌细胞系和人类肺腺癌组织中表达上调。GPRC5A基因敲除小鼠的气管上皮细胞及肺组织的ABCB1表达高于野生型小鼠。与GPRC5A野生型小鼠的气管上皮细胞相比,GPRC5A基因敲除小鼠的气管上皮细胞对塔立奇达和多柔比星更敏感。注射移植细胞28天后,接受ABCB1基因敲除细胞移植的GPRC5A-/-C57BL/6小鼠的肺肿瘤的体积和重量均明显低于野生型细胞移植小鼠(P=0.0043,P=0.0060)。此外,免疫荧光和免疫沉淀实验表明,GPRC5A通过直接结合方式调控ABCB1的表达。结论GPRC5A通过抑制ABCB1表达降低肺腺癌增殖。GPRC5A调节ABCB1表达的途径有待研究。
文摘背景:诱导骨髓基质干细胞成骨条件的优化与探讨是再生医学研究的热点。前期实验发现Wnt7b在骨发育中的作用,此次实验是前期工作的延续。目的:构建Wnt7b重组反转录病毒载体,观察其在C3H10T1/2中的表达。设计、时间及地点:细胞学体外观察,于2005-01/2008-08在华盛顿大学医学院和同济大学附属第十人民医院中心实验室完成。材料:pXy-Wnt7b购于ATCC公司,载体pCIG-IRES-EGFP,pLef-Luciferase,pCMV-Rennilla,反转录病毒载体pSFG和包装细胞GP293由华盛顿大学医学院提供。方法:用多步亚克隆技术构建目的基因Wnt7b和标记基因加强型绿色荧光蛋白(enhanced green fluorescent protein,EGFP)双表达重组反转录病毒载体pSFG-Wnt7b-IRES-EGFP,在条件培养液中经GP293包装,并在常规培养液中释放出假病毒并将其转染C3H10T1/2细胞,检测成骨活性诱导中的作用和荧光素酶报告基因检测信号转导通路。主要观察指标:①Wnt7b重组反转录病毒转染C3H10T1/2细胞的表达。②Wnt7b诱导C3H10T1/2碱性磷酸酶生成分析。③Wnt7b信号转导分析。结果:构建目的基因的Wnt7b和标记基因EGFP双表达重组反转录病毒载体能够高效地表达,转染C3H10T1/2细胞后能诱导碱性磷酸酶的生成。Wnt7b信号转导分析可见Wnt7b成骨作用通过Noncanonical途径。结论:Wnt7b在C3H10T1/2中能高效表达,能显著诱导骨发育的重要标志--碱性磷酸酶的生成,Noncanonical途径在其中起重要作用。
基金Supported by Grant-in-Aid from the Ministry of Health,Labor and Welfare of Japan
文摘AIM To clarify the association between aldo-keto reductase family 1 member B10(AKR1B10) expression and hepatocarcinogenesis after hepatitis C virus eradication.METHODS In this study,we enrolled 303 chronic hepatitis C patients who had achieved sustained virological response(SVR) through interferon-based antiviral therapy. Pretreatment AKR1B10 expression in the liver was immunohistochemically assessed and quantified as a percentage of positive staining area by using image-analysis software. A multivariate Cox analysis was used to estimate the hazard ratios(HRs) of AKR1B10 expression for hepatocellular carcinoma(HCC) development after achieving SVR. The cumulative incidences of HCC development were evaluated using Kaplan-Meier analysis and the log-rank test.RESULTS Of the 303 chronic hepatitis C patients,153(50.5%) showed scarce hepatic AKR1B10 expression,quantified as 0%,which was similar to the expression in control normal liver tissues. However,the remaining 150 patients(49.5%) exhibited various degrees of AKR1B10 expression in the liver,with a maximal AKR1B10 expression of 73%. During the median follow-up time of 3.6 years(range 1.0-10.0 years),8/303 patients developed HCC. Multivariate analysis revealed that only high AKR1B10 expression(≥ 8%) was an independent risk factor for HCC development(HR = 15.4,95%CI: 1. 8- 1 3 2. 5,P = 0. 0 1 2). T h e 5- y e a r c u m u l a t i v e incidences of HCC development were 13.7% and 0.5% in patients with high and low AKR1B10 expression,respectively(P < 0.001). During the follow-up period after viral eradication,patients expressing high levels of AKR1B10 expressed markedly higher levels of alanine aminotransferase and α-fetoprotein than did patients exhibiting low AKR1B10 expression.CONCLUSION Chronic hepatitis C patients expressing high levels of hepatic AKR1B10 had an increased risk of HCC development even after SVR.
基金supported by funds from the National Institutes of Health (1R15CA143701)St.John's University Research Seed Grant(579-1110-7002) to Dr.Zhe-Sheng Chen.Drs.Suneet ShuklaSuresh V.Ambudkar were supported by the Intramural Research Program,Center for Cancer Research, National Cancer Institute,National Institutes of Health
文摘Introduction:ATP-binding cassette subfamily B member 1(ABCB1) and subfamily C member 10(ABCCIO) proteins are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substances and chemotherapeutic drugs out of cells.Cabazitaxel is a novel taxane that differs from paclitaxel by its lower affinity for ATP-binding cassette(ABC) transporters.Methods:We determined the effects of cabazitaxel,a novel tubulin-binding taxane,and paclitaxel on paclitaxelresistant,ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant,ABCC10-overexpressing HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the ABCB1 transporter.Results:Decreased resistance to cabazitaxel compared with paclitaxel was observed in KB-C2,LLC-MDR1-WT,and HEK293/ABCC10 cells.Moreover,cabazitaxel had low efficacy,whereas paclitaxel had high efficacy in stimulating the ATPase activity of ABCB1,indicating a direct interaction of both drugs with the transporter.Conclusion:ABCB1 and ABCC10 are not primary resistance factors for cabazitaxel compared with paclitaxel,suggesting that cabazitaxel may have a low affinity for these efflux transporters.
